Novartis AG ADR (NVS)vsPhreesia Inc (PHR)
NVS
Novartis AG ADR
$154.61
-1.48%
HEALTHCARE · Cap: $291.32B
PHR
Phreesia Inc
$12.26
-0.08%
HEALTHCARE · Cap: $698.47M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 11339% more annual revenue ($56.69B vs $495.59M). NVS leads profitability with a 22.5% profit margin vs 1.9%. NVS trades at a lower P/E of 23.1x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PHR
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.9%
Fair Value
$92.92
Current Price
$154.61
$61.69 premium
Margin of Safety
+72.0%
Fair Value
$44.71
Current Price
$12.26
$32.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.6% — below average capital efficiency
1.9% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : PHR
The strongest argument for PHR centers on Debt/Equity, Price/Book. Revenue growth of 12.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PHR
The primary concerns for PHR are EPS Growth, Market Cap, Return on Equity. A P/E of 70.6x leaves little room for execution misses. Thin 1.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
PHR carries more volatility with a beta of 0.84 — expect wider price swings.
PHR is growing revenue faster at 12.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 44/100), backed by strong 22.5% margins. PHR offers better value entry with a 72.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Phreesia Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Phreesia, Inc. provides integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?